RESUMEN
Objectives: Primaquine is metabolized by the cytochrome P450-2D6 enzyme (CYP2D6) to an active primaquine-5,6-orthoquinone (POQ). No relationships of CYP2D6 polymorphisms with the pharmacokinetics of primaquine and POQ were reported in the Thai population. Methods: We evaluated the genetic distribution of CYP2D6 in 345 Thai army populations together with the pharmacokinetic profiles of primaquine and POQ in plasma and urine (n = 44, descriptive data are presented in median (range)). All dose-related pharmacokinetic parameters were normalized by primaquine dose per body weight before statistical analysis. Results: CYP2D6*10 was the allele observed with the highest frequency (56.62%) corresponding to CYP2D6*10/*10 (32.94%) and CYP2D6*1/*10 (27.94%) genotypes. CYP2D6 intermediate metabolizers (CYP2D6 IM) were found in 44.41% of the cohort and had an increase in the cumulative amount of primaquine excreted (CAE) in urine compared to normal metabolizers of CYP2D6 (CYP2D6 NM); (CYP2D6 IM vs. CYP2D6 NM: 2444 (1697-3564) vs. 1757 (1092-2185) µg/mg/kg, p = 0.039), a reduction in urine CAE of POQ (CYP2D6 IM vs CYP2D6 NM: 115 (46-297) vs. 318 (92-498) µg/mg/kg, p = 0.047) and a reduction in the POQ/primaquine CAE ratio in urine (CYP2D6 IM vs. CYP2D6 NM: 0.06 (0.01-0.11) vs. 0.16 (0.06-0.26), p = 0.009). No significant differences were found in the pharmacokinetic profiles of plasma primaquine and POQ. Conclusions: The CYP2D6 polymorphisms influenced the changes in primaquine and POQ that were noticeable in the urine, supporting the role of the CYP2D6 gene testing before drug administration.
RESUMEN
BACKGROUND: Diagnosis of stress generally involves uses of questionnaires which can provide biased results. The more reliable approach relies on observation of individual symptoms by psychiatrists which is time consuming and could not be applicable for massive scale screening tests. This research established alternative approaches with gas chromatography-ion mobility spectrometry (GC-IMS) and electronic nose (e-nose) to perform fast stress screening based on fingerprinting of highly volatile compounds in headspaces of sweat. The investigated samples were obtained from 154 female nurse volunteers who also provided the data of questionnaire-based mental health scores with the high stress cases confirmed by psychiatrists. RESULTS: The interviews by psychiatrists revealed 14 volunteers with high stress. Their axillary sweat samples and that from 32 nurses with low/moderate stress (controls) were collected onto cotton rods and analysed with GC-IMS. The possible marker peaks were selected based on the accuracy data. They were tentatively identified as ammonia, diethyl ether, methanol, octane, pentane, acetone and dimethylamine which could involve different endogenous mechanisms or the relationships with the local microbiomes. The data were further analysed using partial least squares discriminant analysis with the receiver operating characteristic curves showing the optimum accuracy, sensitivity and selectivity of 87%, 86% and 88%, respectively. Providing that the samples were obtained from the nurses without deodorant uses, the high stress cases could be screened using e-nose sensors with the accuracy of 89%. The sensor responses could be correlated with the marker peak area data in GC-IMS with the coefficients ranging from -0.70 to 0.80. SIGNIFICANCE: This represents the first investigation of highly volatile compound markers in sweat for high stress screening. The established methods were simple, reliable, rapid and non-invasive, which could be further adapted into the portable platform of e-nose sensors with the practical application to perform the screening tests for nurses in Phra Nakorn Si Ayutthaya hospital, Thailand.